SCHEMBL15769484

SCHEMBL15769484

N#Cc1cc(Nc2ncc(C(F)(F)F)c(NC[C@@H]3CCCN4CCCC[C@H]34)n2)ccc1C1CC1

nearest known ligand 0.49

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 17/20 0.49
PTK2 Q05397 2/20 0.43
PRKCQ Q04759 1/20 0.43
FLT3 P36888 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15769975 0.90 PRKCQ (0.47) PTK2PRKCQFLT3
SCHEMBL15769746 0.90 CHEK1 (0.51) CHEK1PTK2PRKCQFLT3
SCHEMBL15769286 0.90 PRKCQ (0.42) PRKCQ
SCHEMBL15769873 0.88 TNK2 (0.46) CHEK1PRKCQ
SCHEMBL15769777 0.88 TNK2 (0.46) CHEK1PRKCQ
SCHEMBL15769467 0.88 TNK2 (0.40) CHEK1PRKCQ
SCHEMBL15769754 0.88 LRRK2 (0.44) CHEK1
SCHEMBL15769386 0.86 CHEK1 (0.50) CHEK1PTK2PRKCQFLT3
SCHEMBL15769863 0.86 PRKCQ (0.38) CHEK1PTK2PRKCQFLT3
SCHEMBL20752214 0.86 PRKCQ (0.38) CHEK1PTK2PRKCQFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2928891-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2019-02-20 EP claimed
US-9062068-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-06-23 US claimed
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2014-06-12 US claimed
EP-2928891-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2019-02-20 EP disclosed
EP-2928891-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2019-02-20 EP disclosed
US-9913843-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2018-03-13 US disclosed
US-9913843-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2018-03-13 US disclosed
US-20150306100-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2015-10-29 US disclosed
US-20150306100-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2015-10-29 US disclosed
US-9062068-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-06-23 US disclosed
US-9062068-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-06-23 US disclosed
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2014-06-12 US disclosed
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2014-06-12 US disclosed
WO-2014089112-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS, INC. (US) 2014-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB CHEK1 350/4885PTK2 175/4885PRKCQ 5/4885
US-20150306100-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB CHEK1 350/4885PTK2 175/4885PRKCQ 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.